Simotinib hydrochloride is a selective, specific, and orally bioavailable EGFR tyrosine kinase inhibitor, with an IC₅₀ of 19.9 nM. Antineoplastic activities^[1].

Simotinib hydrochloride inhibits in a dose-dependent manner EGFR and the growth of human A431 tumor cells with high expression of EGFR, with no significant activity on other investigated kinases^[1].

Shanghai Jinpan Biotech Co Ltd has not independently confirmed the accuracy of these methods. They are for reference only.

Simotinib hydrochloride has been shown to exert its antitumor activity by inhibiting EGFR phosphorylation in nude xenograft model^[1].

Shanghai Jinpan Biotech Co Ltd has not independently confirmed the accuracy of these methods. They are for reference only.

537.41

C₂₅H₂₇Cl₂FN₄O₄

1538617-88-7

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Hu XS, et al. Safety, tolerability, and pharmacokinetics of simotinib, a novel specific EGFR tyrosine kinase inhibitor, in patients with advanced non-small cell lung cancer: results of a phase Ib trial. Cancer Manag Res. 2019;11:4449-4459. Published 2019 May 13.